BR112012025581A2 - implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral - Google Patents

implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral

Info

Publication number
BR112012025581A2
BR112012025581A2 BR112012025581A BR112012025581A BR112012025581A2 BR 112012025581 A2 BR112012025581 A2 BR 112012025581A2 BR 112012025581 A BR112012025581 A BR 112012025581A BR 112012025581 A BR112012025581 A BR 112012025581A BR 112012025581 A2 BR112012025581 A2 BR 112012025581A2
Authority
BR
Brazil
Prior art keywords
implant
sustained release
drug delivery
intracameral
release reservoir
Prior art date
Application number
BR112012025581A
Other languages
English (en)
Inventor
Liu Hui
A Burke James
r robinson Michael
M Hughes Patrick
Shi Ruwen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112012025581A2 publication Critical patent/BR112012025581A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral. a presente invenção fornece um implante de liberação sustentada para utilização intraocular para tratar pressão intraocular elevada, cujo implante é configurado para administração vítrea intracameral ou anterior a um paciente com pressão intraocular elevada (iop), o referido implante compreendendo um núcleo de um agente anti-hipertensivo rodeado por um polímero o qual limta a taxa de passagem do agente anti-hipertensivo do implante para o olho do referido paciente e o referido implante fornece uma taxa linear de liberação de quantidades terapeuticamente eficazes do referido agente anti-hipertensivo paa o olho durante um período de tempo entre 14 dias e 365 dias.
BR112012025581A 2010-04-06 2011-04-05 implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral BR112012025581A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32142210P 2010-04-06 2010-04-06
PCT/US2011/031265 WO2011127064A2 (en) 2010-04-06 2011-04-05 Sustained-release reservoir implants for intracameral drug delivery

Publications (1)

Publication Number Publication Date
BR112012025581A2 true BR112012025581A2 (pt) 2019-09-24

Family

ID=44065364

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025581A BR112012025581A2 (pt) 2010-04-06 2011-04-05 implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral

Country Status (10)

Country Link
US (3) US20130017243A1 (pt)
EP (1) EP2555749B1 (pt)
JP (2) JP2013523821A (pt)
KR (1) KR20130086131A (pt)
CN (1) CN102905688B (pt)
AU (1) AU2011237788A1 (pt)
BR (1) BR112012025581A2 (pt)
CA (1) CA2795706A1 (pt)
RU (1) RU2012146630A (pt)
WO (1) WO2011127064A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2012071476A2 (en) * 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
ES2921527T3 (es) 2009-06-03 2022-08-29 Forsight Vision5 Inc Administración de fármaco en segmento anterior
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
WO2012149287A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Solvent cast film sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9283231B2 (en) 2013-01-31 2016-03-15 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure of glaucoma
AU2014216112B2 (en) * 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
CN105073153B (zh) * 2013-03-15 2018-10-30 阿勒根公司 含有前列腺胺的眼内植入物
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CN105792812B (zh) * 2013-11-14 2020-10-23 眼科制药公司 眼部装置
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
WO2016069898A1 (en) * 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
CN104587850A (zh) * 2015-01-11 2015-05-06 王丽莉 一种聚偏氟乙烯中空纤维膜的制备方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
RU2620249C1 (ru) * 2015-12-17 2017-05-23 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Многослойный биодеградируемый глазной имплантат с дозированным высвобождением лекарственного вещества и способ его изготовления
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2018064578A1 (en) * 2016-09-30 2018-04-05 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112020007006A2 (pt) * 2017-10-13 2020-10-06 Alexion Pharmaceuticals, Inc. métodos para o tratamento de doenças associadas com ciliopatias
RU185437U1 (ru) * 2018-04-12 2018-12-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Устройство для герметизации капсул алюминиевых
WO2019222482A1 (en) * 2018-05-16 2019-11-21 Spirox, Inc. Allergic rhinitis drug delivery implant
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11975087B2 (en) * 2020-03-30 2024-05-07 Colgate-Palmolive Company Sulfate-free personal care compositions and methods for preventing and treating pollution damage to skin
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
MXPA02002338A (es) * 1999-10-21 2002-07-30 Alcon Universal Ltd Dispositivo para la entrega de drogas.
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CA2484632C (en) * 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
EP1592411A2 (en) * 2003-01-24 2005-11-09 Control Delivery Systems, Inc. Controlled release of highly soluble agents
WO2004066979A2 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
PL1696822T3 (pl) * 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
EP1868661A1 (en) * 2005-04-08 2007-12-26 SurModics, Inc. Sustained release implants for subretinal delivery
AU2006294486B2 (en) * 2005-09-28 2012-11-29 The Trustees Of The University Of Pennsylvania Self-assembled biodegradable polymersomes
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080299176A1 (en) * 2007-05-30 2008-12-04 Yu-Chin Lai Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers
DK2207529T3 (en) * 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
WO2011075481A1 (en) * 2009-12-16 2011-06-23 Allergan, Inc. Intracameral devices for sustained delivery

Also Published As

Publication number Publication date
US20150104491A1 (en) 2015-04-16
KR20130086131A (ko) 2013-07-31
CA2795706A1 (en) 2011-10-13
EP2555749B1 (en) 2016-10-26
WO2011127064A2 (en) 2011-10-13
CN102905688B (zh) 2015-11-25
US20160256382A1 (en) 2016-09-08
WO2011127064A3 (en) 2012-10-26
JP2015166361A (ja) 2015-09-24
CN102905688A (zh) 2013-01-30
EP2555749A2 (en) 2013-02-13
JP2013523821A (ja) 2013-06-17
AU2011237788A1 (en) 2012-11-01
RU2012146630A (ru) 2014-05-20
US20130017243A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
MX2019002861A (es) Composicion farmaceutica.
BR112012026535A2 (pt) redução de pressão intraocular com implantes de bimatoprost intracameral
UA106593C2 (uk) Пристрій для пролонгованого введення ліків, який містить полімери на основі поліуретану, та спосіб його виготовлення
WO2005070008A8 (en) Polymer no donor predrug nanofiber coating for medical devices and therapy
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
BR112012026886A2 (pt) dispositivo de injeção automático usável para distribuição controlada de agentes terapêuticos
NZ603185A (en) Methods and devices for drug delivery to ocular tissue using microneedle
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
DK2319517T3 (da) Anvendelse af prodrugs til okulær, intravenøs administration
EP4302734A3 (en) Ocular delivery systems and methods
ME02414B (me) Tretman kronove bolesti lakvinimodom
CO6400201A2 (es) Suministro liberado sostenido de uno o más agentes
WO2012071476A3 (en) Drug eluting ocular implant
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
BR112015022161A2 (pt) implante intraocular contendo prostamida
BR112014029330A2 (pt) métodos, sistemas e dispositivos para administração de fármacos e oclusão vascular
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
EP4295906A3 (en) Treatment of restenosis using temsirolimus
BR112022017998A2 (pt) Formulações de liberação controlada compreendendo drotaverina ou sal da mesma
EP4031113A4 (en) THERAPEUTIC USES AND METHODS OF ADMINISTRATION OF VISCOUS COMPOSITIONS DURING PRE- AND POST-SURGICAL PERIODS, FOR THE TREATMENT OF SENSITIVE DISEASES OF THE EAR, NOSE AND THROAT
BRPI0409293A (pt) medicamento para a prevenção ou tratamento de doenças angiogênicas intraoculares

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.